tiprankstipranks
Trending News
More News >
Euroapi SA (FR:EAPI)
:EAPI
France Market

Euroapi SA (EAPI) Earnings Dates, Call Summary & Reports

Compare
11 Followers

Earnings Data

Report Date
Jul 28, 2026
Before Open (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
Last Year’s EPS
-0.3
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Mar 03, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
Balanced call: the company demonstrated clear execution on cost discipline, cash generation, sustainability validation and portfolio quality improvements (core EBITDA +31%, net cash up to EUR 68.2m, SBTi validation, 66% differentiated sales). However, meaningful top-line decline, substantial impairments (EUR 77.8m), a widened net loss (EUR 211.2m) and continued CDMO early-stage underperformance create significant near-term challenges, with management guiding to ~10% sales decline in 2026 and signaling that some 2027 targets will be missed. The positives on operational control and liquidity are offset by material revenue and profit headwinds.
Company Guidance
The company reiterated 2026 guidance saying net sales will decline by about 10% on a comparable basis (with ~90% of that decrease driven by its deliberate portfolio rationalization), noting the prior discontinuations drove ~EUR 70m of lost sales in 2025 (including ~EUR 20m of stockpiling) and that residual revenue of EUR 10–15m from those SKUs is expected in 2026 (implying a EUR 55–60m headwind); management expects to hold full‑year 2026 core EBITDA margin roughly flat versus 2025’s 7.8% (core EBITDA EUR 66.2m on EUR 848.2m net sales in 2025), target a CapEx/sales ratio around 8% (2025 CapEx was EUR 77m, ~9% of sales), and absorb planned cash restructuring costs of ~EUR 100m over 2026–27; other relevant 2025 metrics referenced as context included EBITDA ~EUR 10m (vs -€44m in 2024), net cash EUR 68.2m (vs EUR 24.6m at end‑2024), cash from operations EUR 128.5m, free cash flow before financing EUR 51.5m, months on hand 7, DSO 36, EUR 56.3m of non‑recurring items (including EUR 36.1m idle costs and EUR 13.7m employee costs), an asset impairment of EUR 77.8m on vitamin B12, 66% of 2025 sales from differentiated products (target 70% by 2027), and that the prior FOCUS‑27 targets (incremental core EBITDA EUR 75–80m by 2027) are now expected to be missed given the lower sales backdrop.
Core EBITDA and Margin Improvement
Core EBITDA reached EUR 66.2 million in 2025, a 31% increase versus 2024, with a core EBITDA margin of 7.8% (up from 5.5%). Reported EBITDA moved to ~EUR 10 million versus negative EUR 44 million in 2024.
Strong Cash Generation and Net Cash Position
Operating cash flow generated EUR 128.5 million in 2025. Free cash flow before financing was EUR 51.5 million (vs EUR 15.0 million in 2024). Net cash position improved to EUR 68.2 million at year-end 2025 from EUR 24.6 million at end-2024.
Working Capital Improvements
Working capital contributed EUR 120.1 million to cash flow, including inventory reduction of EUR 38.9 million and trade receivables reduction of EUR 45.4 million (of which EUR 26.5 million was factored). Months on hand stood at 7 and DSO at 36.
Sustained Cost Discipline and OpEx Savings
The company sustainably reduced external expenses and personnel costs; ~EUR 20 million of OpEx savings delivered over the past two years and 380 positions removed as part of footprint/organization simplification.
CapEx Discipline with Targeted Strategic Investment
CapEx was EUR 77 million in 2025 (≈9% of net sales), down from EUR 108 million in 2024 and EUR 137 million in 2023. 65% of 2025 CapEx was dedicated to growth/performance projects (peptides, oligonucleotides, prostaglandins, corticosteroids).
Sustainability Milestones Achieved
Near-term carbon emission reduction targets were validated by SBTi; company achieved half of its targeted Scope 1 & 2 reductions in 2025 and exceeded its Scope 3 target.
Portfolio Quality and FOCUS-27 Progress
66% of 2025 sales came from differentiated products (up from 57% at end-2023) and the company is on track toward a 70% target by 2027. CDMO pipeline quality improved with ~70% of projects late-stage; Haverhill divested and industrial consolidation actions executed.
Improved Financial Expenses and Financing
Net financial expenses improved by EUR 7.5 million versus 2024 and reported cost of debt decreased to around EUR 3 million following refinancing and financing plan implementation.

Euroapi SA (FR:EAPI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

FR:EAPI Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 28, 2026
2026 (Q2)
- / -
-0.301
Mar 03, 2026
2025 (Q4)
- / -1.93
-1.006-91.75% (-0.92)
Jul 29, 2025
2025 (Q2)
- / -0.30
-0.36918.43% (+0.07)
Mar 03, 2025
2024 (Q4)
- / -1.01
-2.66262.21% (+1.66)
Jul 30, 2024
2024 (Q2)
- / -0.37
0.669-155.16% (-1.04)
Feb 28, 2024
2023 (Q4)
- / -2.66
-0.127-1996.06% (-2.54)
Aug 01, 2023
2023 (Q2)
- / 0.67
0.18271.67% (+0.49)
Mar 08, 2023
2022 (Q4)
0.16 / -0.13
Sep 01, 2022
2022 (Q2)
- / 0.18
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

FR:EAPI Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 03, 2026
€2.07€1.95-5.51%
Jul 29, 2025
€3.13€3.05-2.56%
Mar 03, 2025
€2.59€2.70+4.25%
Jul 30, 2024
€3.35€3.72+11.04%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Euroapi SA (FR:EAPI) report earnings?
Euroapi SA (FR:EAPI) is schdueled to report earning on Jul 28, 2026, Before Open (Confirmed).
    What is Euroapi SA (FR:EAPI) earnings time?
    Euroapi SA (FR:EAPI) earnings time is at Jul 28, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Euroapi SA stock?
          The P/E ratio of Euroapi SA is N/A.
            What is FR:EAPI EPS forecast?
            Currently, no data Available